CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
19.86
0.66%
Market Trading Hours* (UTC) Open now
Closes on Friday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.15
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

AnaptysBio Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 19.78
Open* 19.83
1-Year Change* -10.76%
Day's Range* 19.83 - 20.52
52 wk Range 13.36-27.48
Average Volume (10 days) 269.26K
Average Volume (3 months) 5.07M
Market Cap 629.57M
P/E Ratio -100.00K
Shares Outstanding 26.58M
Revenue 14.96M
EPS -5.41
Dividend (Yield %) N/A
Beta -0.30
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 18, 2024 19.78 -0.89 -4.31% 20.67 21.72 19.74
Apr 17, 2024 21.40 0.73 3.53% 20.67 21.44 20.66
Apr 16, 2024 21.31 -0.16 -0.75% 21.47 21.98 20.99
Apr 15, 2024 21.23 -1.22 -5.43% 22.45 22.82 20.99
Apr 12, 2024 22.68 -1.98 -8.03% 24.66 24.69 22.48
Apr 11, 2024 24.68 0.88 3.70% 23.80 25.26 23.78
Apr 10, 2024 22.13 1.26 6.04% 20.87 22.37 20.50
Apr 9, 2024 21.50 1.53 7.66% 19.97 21.65 19.97
Apr 8, 2024 20.63 0.13 0.63% 20.50 21.01 20.50
Apr 5, 2024 21.00 0.64 3.14% 20.36 21.44 20.36
Apr 4, 2024 21.29 1.22 6.08% 20.07 21.93 20.07
Apr 3, 2024 20.62 0.00 0.00% 20.62 20.82 20.12
Apr 2, 2024 20.80 0.75 3.74% 20.05 20.92 20.04
Apr 1, 2024 21.28 -1.22 -5.42% 22.50 22.50 20.39
Mar 28, 2024 22.46 1.10 5.15% 21.36 22.78 20.74
Mar 27, 2024 21.26 -0.31 -1.44% 21.57 21.78 20.78
Mar 26, 2024 21.53 0.45 2.13% 21.08 21.78 20.60
Mar 25, 2024 21.04 -0.29 -1.36% 21.33 21.90 21.01
Mar 22, 2024 21.61 -2.71 -11.14% 24.32 24.32 21.54
Mar 21, 2024 24.41 0.36 1.50% 24.05 24.64 23.94

AnaptysBio Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 AnaptysBio Inc Earnings Release
Q1 2024 AnaptysBio Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

16:00

Country

US

Event

AnaptysBio Inc Annual Shareholders Meeting
AnaptysBio Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 5, 2024

Time (UTC)

20:00

Country

US

Event

Q2 2024 AnaptysBio Inc Earnings Release
Q2 2024 AnaptysBio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 10.287 63.175 75 8 5
Revenue 10.287 63.175 75 8 5
Total Operating Expense 125.441 119.989 98.879 115.432 71.722
Selling/General/Admin. Expenses, Total 36.643 21.493 18.854 16.094 15.526
Research & Development 88.798 98.496 80.025 99.338 56.196
Operating Income -115.154 -56.814 -23.879 -107.432 -66.722
Interest Income (Expense), Net Non-Operating 7.55 0.431 3.959 9.943 5.033
Other, Net -21.096 -1.413 -0.011 0.001 -0.159
Net Income Before Taxes -128.7 -57.796 -19.931 -97.488 -61.848
Net Income After Taxes -128.724 -57.796 -19.931 -97.336 -61.656
Net Income Before Extra. Items -128.724 -57.796 -19.931 -97.336 -61.656
Net Income -128.724 -57.796 -19.931 -97.336 -61.656
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -128.724 -57.796 -19.931 -97.336 -61.656
Income Available to Common Incl. Extra. Items -128.724 -57.796 -19.931 -97.336 -61.656
Diluted Net Income -128.724 -57.796 -19.931 -97.336 -61.656
Diluted Weighted Average Shares 28.165 27.431 27.302 27.059 24.673
Diluted EPS Excluding Extraordinary Items -4.57035 -2.10696 -0.73002 -3.59718 -2.49893
Diluted Normalized EPS -4.57035 -2.10696 -0.73002 -3.59718 -2.49893
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.46 1.374 6.808 1.293 1.216
Revenue 3.46 1.374 6.808 1.293 1.216
Total Operating Expense 43.603 45.775 32.781 30.926 29.015
Selling/General/Admin. Expenses, Total 10.68 10.818 9.407 8.862 8.171
Research & Development 32.923 34.957 23.374 22.064 20.844
Operating Income -40.143 -44.401 -25.973 -29.633 -27.799
Interest Income (Expense), Net Non-Operating 4.653 4.486 3.839 2.262 1.107
Other, Net -4.355 -4.34 -4.255 -6.131 -5.862
Net Income Before Taxes -39.845 -44.255 -26.389 -33.502 -32.554
Net Income After Taxes -39.845 -44.255 -26.413 -33.502 -32.554
Net Income Before Extra. Items -39.845 -44.255 -26.413 -33.502 -32.554
Net Income -39.845 -44.255 -26.413 -33.502 -32.554
Income Available to Common Excl. Extra. Items -39.845 -44.255 -26.413 -33.502 -32.554
Income Available to Common Incl. Extra. Items -39.845 -44.255 -26.413 -33.502 -32.554
Diluted Net Income -39.845 -44.255 -26.413 -33.502 -32.554
Diluted Weighted Average Shares 26.629 27.953 28.447 28.289 28.204
Diluted EPS Excluding Extraordinary Items -1.4963 -1.58319 -0.9285 -1.18428 -1.15423
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.4963 -1.58319 -0.9285 -1.18428 -1.15423
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 447.205 553.876 396.561 377.733 434.216
Cash and Short Term Investments 441.241 548.097 393.653 374.227 427.082
Cash & Equivalents 71.308 495.729 250.456 171.017 113.596
Total Receivables, Net 1.419 0.876 0 0.174
Prepaid Expenses 4.545 4.903 2.908 3.506 6.96
Total Assets 610.383 643.07 416.552 435.197 508.997
Property/Plant/Equipment, Total - Net 19.987 21.841 2.127 3.02 1.445
Property/Plant/Equipment, Total - Gross 25.563 26.763 7.072 7.699 5.642
Accumulated Depreciation, Total -5.576 -4.922 -4.945 -4.679 -4.197
Other Long Term Assets, Total 0.256 0.256 0.318 0.139 0.208
Total Current Liabilities 26.054 16.099 19.821 29.535 21.836
Accounts Payable 2.784 1.741 4.217 16.237 5.443
Accrued Expenses 23.27 14.358 15.604 11.923 8.761
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.058
Total Liabilities 348.28 286.642 19.821 30.189 22.632
Total Long Term Debt 0 0 0 0 0.625
Long Term Debt 0.625
Other Liabilities, Total 322.226 270.543 0 0.654 0.171
Total Equity 262.103 356.428 396.731 405.008 486.365
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.029 0.028 0.027 0.027 0.027
Additional Paid-In Capital 717.797 678.575 660.665 648.669 633.251
Retained Earnings (Accumulated Deficit) -450.477 -321.753 -263.957 -244.026 -146.69
Total Liabilities & Shareholders’ Equity 610.383 643.07 416.552 435.197 508.997
Total Common Shares Outstanding 28.513 27.647 27.356 27.255 26.922
Short Term Investments 369.933 52.368 143.197 203.21 313.486
Long Term Investments 142.935 67.097 17.546 54.305 73.128
Current Port. of LT Debt/Capital Leases 0 1.375 7.574
Other Equity, Total -5.246 -0.422 -0.004 0.338 -0.223
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 428 438.535 437.154 447.205 450.444
Cash and Short Term Investments 413.047 429.486 431.151 441.241 442.966
Cash & Equivalents 26.295 35.206 94.562 71.308 58.547
Short Term Investments 386.752 394.28 336.589 369.933 384.419
Total Receivables, Net 3.269 3.182 1.523 1.419 1.18
Prepaid Expenses 11.684 5.867 4.48 4.545 6.298
Other Current Assets, Total
Total Assets 487.326 517.1 551.792 610.383 618.503
Property/Plant/Equipment, Total - Net 18.867 19.07 19.453 19.987 20.292
Property/Plant/Equipment, Total - Gross 24.93 24.975 25.196 25.563 25.704
Accumulated Depreciation, Total -6.063 -5.905 -5.743 -5.576 -5.412
Long Term Investments 40.203 59.239 94.929 142.935 147.511
Other Long Term Assets, Total 0.256 0.256 0.256 0.256 0.256
Total Current Liabilities 39.178 41.631 35.795 26.054 21.063
Accounts Payable 6.521 4.761 3.168 2.784 3.006
Accrued Expenses 32.657 36.87 32.627 23.27 18.057
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 366.943 368.65 360.699 348.28 340.884
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 327.765 327.019 324.904 322.226 319.821
Total Equity 120.383 148.45 191.093 262.103 277.619
Preferred Stock - Non Redeemable, Net 0 0
Common Stock 0.027 0.027 0.027 0.029 0.028
Additional Paid-In Capital 694.591 686.611 689.065 717.797 707.662
Retained Earnings (Accumulated Deficit) -571.885 -534.577 -494.732 -450.477 -424.064
Other Equity, Total -2.35 -3.611 -3.267 -5.246 -6.007
Total Liabilities & Shareholders’ Equity 487.326 517.1 551.792 610.383 618.503
Total Common Shares Outstanding 26.575 26.531 27.018 28.513 28.354
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -128.724 -57.796 -19.931 -97.336 -61.656
Cash From Operating Activities -73.593 -45.92 -14.157 -69.517 -48.506
Cash From Operating Activities 0.675 0.619 0.559 0.514 0.315
Non-Cash Items 47.617 18.746 11.986 10.454 9.374
Cash Interest Paid 0 0 0.004 0.424 1.043
Changes in Working Capital 6.839 -7.489 -6.771 16.851 3.461
Cash From Investing Activities -394.845 38.835 94.475 131.431 -142.451
Capital Expenditures -0.358 -1.366 -0.569 -0.805 -1.063
Other Investing Cash Flow Items, Total -394.487 40.201 95.044 132.236 -141.388
Cash From Financing Activities 44.017 252.298 -0.879 -4.493 223.364
Financing Cash Flow Items 32.19 249.745 0 0 -0.182
Issuance (Retirement) of Stock, Net 11.827 2.553 0.496 3.007 230.421
Issuance (Retirement) of Debt, Net 0 0 -1.375 -7.5 -6.875
Net Change in Cash -424.421 245.213 79.439 57.421 32.407
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -44.255 -128.724 -102.311 -68.809 -36.255
Cash From Operating Activities -24.568 -73.593 -62.908 -45.161 -21.014
Cash From Operating Activities 0.166 0.675 0.491 0.325 0.162
Non-Cash Items 11.432 47.617 37.982 25.941 13.168
Cash Interest Paid 0
Changes in Working Capital 8.089 6.839 0.93 -2.618 1.911
Cash From Investing Activities 85.396 -394.845 -416.342 -383.908 -312.912
Capital Expenditures -0.175 -0.358 -0.183 -0.133 -0.055
Other Investing Cash Flow Items, Total 85.571 -394.487 -416.159 -383.775 -312.857
Cash From Financing Activities -37.574 44.017 42.068 5.041 4.609
Issuance (Retirement) of Stock, Net -36.261 11.827 8.408 5.709 4.844
Issuance (Retirement) of Debt, Net 0
Net Change in Cash 23.254 -424.421 -437.182 -424.028 -329.317
Financing Cash Flow Items -1.313 32.19 33.66 -0.668 -0.235

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AnaptysBio Company profile

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical stage biotechnology company. The Company is developing immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops its product candidates using its antibody discovery technology platform, which is based upon the natural process of antibody generation, known as somatic hypermutation (SHM), and replicates this natural process of antibody generation in vitro. Its product pipeline includes Imsidolimab, ANB030 (Rosnilimab), ANB032, JEMPERLI, GSK4069889 (cobolimab), GSK4074386 and CC-90006. its Imsidolimab is an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of multiple dermatological inflammatory diseases. ANB030 is an antibody that binds PD-1 in an agonistic manner to suppress T cell activity and anti-inflammatory effects in vivo.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AnaptysBio Inc revenues decreased 16% to $63.2M. Net loss increased from $19.9M to $57.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 22% to $92.6M (expense), Interest income decrease of 89% to $431K (income).

Industry: Bio Therapeutic Drugs

10770 Wateridge Circle, Suite 210
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

Gold

2,389.89 Price
+0.350% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.50 Price
-1.060% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

64,297.45 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,205.50 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading